WolfeR.A., AshbyV.B., MilfordE.L.. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med.1999; 341(23): 1725–1730.
2.
VanholderR., De SmetR., GlorieuxG.. European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int.2003; 63(5): 1934–1943.
3.
SaitoA., SawadaK., FujimuraS.Present status and future perspectives on the development of bioartificial kidneys for the treatment of acute and chronic renal failure patients. Hemodial Int.2011; 15(2): 183–192.
4.
AebischerP., IpT.K., PanolG., GallettiP.M.The bioartificial kidney: progress towards an ultrafiltration device with renal epithelial cells processing. Life Support Syst.1987; 5(2): 159–168.
5.
HumesH.D., BuffingtonD.A., MacKayS.M., FunkeA.J., WeitzelW.F.Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol.1999; 17(5): 451–455.
6.
HumesH.D., WeitzelW.F., FissellW.H.Renal cell therapy in the treatment of patients with acute and chronic renal failure. Blood Purif.2004; 22(1): 60–72.
7.
JansenJ., FedecostanteM., WilmerM.J., van den HeuvelL.P., HoenderopJ.G., MasereeuwR.Biotechnological challenges of bioartificial kidney engineering. Biotechnol Adv.2014; 32(7): 1317–1327.
8.
ShitaraY., HorieT., SugiyamaY.Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci.2006; 27(5): 425–446.
9.
TaharaH., KusuharaH., EndouH.. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther.2005; 315(1): 337–345.
10.
WilmerM.J., SaleemM.A., MasereeuwR.. Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res.2010; 339(2): 449–457.
11.
JansenJ., SchophuizenC.M., WilmerM.J.. A morphological and functional comparison of proximal tubule cell lines established from human urine and kidney tissue. Exp Cell Res.2014; 323(1): 87–99.
12.
MasereeuwR., MutsaersH.A., ToyoharaT.. The kidney and uremic toxin removal: glomerulus or tubule?Semin Nephrol.2014; 34(2): 191–208.
13.
Sánchez-RomeroN., SchophuizenC.M., GiménezI., MasereeuwR.In vitro systems to study nephropharmacology: 2D versus 3D models. Eur J Pharmacol.2016; 790: 36–45.
14.
NieskensT.T., PetersJ.G., SchreursM.J.. A Human Renal Proximal Tubule Cell Line with Stable Organic Anion Transporter 1 and 3 Expression Predictive for Antiviral-Induced Toxicity. AAPS J.2016; 18(2): 465–475.
15.
SchophuizenC.M., De NapoliI.E., JansenJ.. Development of a living membrane comprising a functional human renal proximal tubule cell monolayer on polyethersulfone polymeric membrane. Acta Biomater.2015; 14: 22–32.
16.
NiM., TeoJ.C., IbrahimM.S.. Characterization of membrane materials and membrane coatings for bioreactor units of bioartificial kidneys. Biomaterials.2011; 32(6): 1465–1476.
17.
SchophuizenC.M., WilmerM.J., JansenJ.. Cationic uremic toxins affect human renal proximal tubule cell functioning through interaction with the organic cation transporter. Pflugers Arch.2013; 465(12): 1701–1714.
18.
CiarimboliG., LancasterC.S., SchlatterE.. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res.2012; 18(4): 1101–1108.
19.
JansenJ., De NapoliI.E., FedecostanteM.. Human proximal tubule epithelial cells cultured on hollow fibers: living membranes that actively transport organic cations. Sci Rep.2015; 5: 16702.
20.
SchlatterE., MönnichV., CetinkayaI.. The organic cation transporters rOCT1 and hOCT2 are inhibited by cGMP. J Membr Biol.2002; 189(3): 237–244.
21.
ChevtchikN.V., FedecostanteM., JansenJ.. Upscaling of a living membrane for bioartificial kidney device. Eur J Pharmacol.2016; 790: 28–35.
JangK.J., MehrA.P., HamiltonG.A.. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol (Camb).2013; 5(9): 1119–1129.
